Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Indexé dans
  • Index Copernic
  • Google Scholar
  • Ouvrir la porte J
  • JournalSeek de génamique
  • RechercheBible
  • Bibliothèque de revues électroniques
  • Recherche de référence
  • Université Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Catalogue en ligne SWB
  • Bibliothèque virtuelle de biologie (vifabio)
  • Publons
  • Fondation genevoise pour l'enseignement et la recherche médicale
  • ICMJE
Partager cette page

Abstrait

Glioblastoma of the Conus Medullaris Following Treatment of Hodgkin's Lymphoma: History of a Case and Literature Review

Pichon B, Champiat S, Aumont M, Loussouarn D, Frénel JS, Mahé MA and Demoor-Goldschmidt C

Purpose: Reports of a glioblastoma arising in a previously irradiated field are rare in the literature, even more so in the conus medullaris of the spinal cord. Method: Case report and review of the literature reporting other radiation-induced intra-medullary glioblastomas. Results: We report a case of glioblastoma of the conus, which subsequently metastasized to the brain, arising in a 45 years old man, nine years after treatment for Hodgkin's lymphoma, which had included the administration of 41 Gy to the brain and spinal cord. Conclusion: Despite a well-conducted treatment by several lines of chemotherapy, the pronostic of radiationinduced glioblastoma is poor especially since these patients often cannot benefit from a re-irradiation due to the maximum dose supported by the spinal cord. Implications of cancer survivors: Associations are now established between therapeutic exposures and specific complications but considerable inter-individual variability is observed for a given therapeutic exposure. In this context, identification of genetic susceptibilities for specific treatment-associated late effect is a very promising future approach. Improvement in our knowledge on genetic susceptibilities may help define more personalized primary therapies that weigh treatment efficacy with the risk of late complications.